Canadian AI Microcap Cut Hospital Drug Alerts by 94%. Now It’s Entering the U.S. (TSXV: SEGN)

WSW, NY, July 16th, 2026, FinanceWire

On June 19, Seegnal Inc. (TSXV: SEGN) said it had begun running its first pilot in the United States, the company's first operating step into the world's largest healthcare market. The move seems modest on its own, a single pilot, but it lands on top of years of large-scale use in Israel, where Seegnal reports its platform now supports roughly 15,000 clinicians in daily clinical practice.

To understand what this might mean for the U.S. market, you have uto understand what Seegnal has built. Seegnal's software plugs into hospital electronic record systems and screens each prescription in real time against the patient's own labs, renal function, diagnoses, age, allergies and medication history, rather than checking one drug against another. That patient-specific approach is what separates it from the drug-safety checks built into legacy clinical decision support software, which typically flag drug-drug pairs regardless of the patient sitting in front of the clinician.

The problem it targets is well documented. Roughly one in twenty patients globally is affected by preventable medication-related harm, according to the World Health Organization, and adverse drug events drive more than 1.5 million U.S. emergency-department visits a year. Legacy alert systems generate so much noise that clinicians override up to 95% of alerts they receive, a pattern known as alert fatigue.

Seegnal's approach has been tested against the incumbent. In a peer-reviewed 2021 study at Brigham and Women's Hospital, published in Drug Safety, researchers compared Seegnal's platform with Epic across 3,801 patients across three cohorts. In the 657-patient inpatient group, Seegnal generated 1,697 alerts versus 27,540 for Epic, a 94% reduction, with specificity of 99% versus 0.3% and 100% sensitivity versus 68.8%. In a separate controlled trial at Leumit Health Services, an Israeli HMO, published in 2017, the system was associated with 5.6% fewer mean hospitalization episodes and 1.5% fewer mean drugs dispensed versus controls, with physicians resolving 42% of the severe drug-safety risks the platform flagged.

*Disseminated on behalf of Seegnal Inc. (TSXV: SEGN). See full disclaimer below.

In Israel, Seegnal reports its platform processes more than 400,000 prescriptions a day across Israeli hospitals and HMOs, with more than 174 million prescriptions analyzed to date. Those operating figures are company-reported and unaudited.

The pilot itself was the follow-through on a letter of intent Seegnal signed in the spring with a U.S. long-term-care operator. Separately, in early June, Seegnal was accepted into the AARP AgeTech Collaborative accelerator, run by the largest nonprofit U.S. organization serving Americans aged 50 and older. The choice of setting is deliberate. Long-term care concentrates exactly the patients Seegnal's platform is built for: older people taking many medications at once, the group at highest risk of preventable drug harm. The WHO projects the global population over 60 to reach 2.1 billion by 2050, roughly double the level in 2020.

Expansion in the Israeli market has continued in parallel. On June 25, Seegnal said it had signed a five-year agreement to deploy its platform across Nazareth Hospital EMMS, a regional trauma center and teaching hospital in northern Israel, supporting approximately 424 clinicians, including 188 physicians and 236 nurses. Because it trains new clinicians, a teaching hospital can embed a prescribing standard early in careers. The Nazareth agreement followed an expanded deployment at Tel Aviv Sourasky Medical Center earlier this year and an extension of the Maccabi Healthcare Services contract through 2031. Recent months have moved on two tracks at once: deeper adoption in Israel and first steps abroad.

The distance between those two tracks is the point worth watching. Seegnal has scaled its platform broadly in one country while remaining early everywhere else, and turning a respected clinical record into U.S. revenue is a different task from building the technology itself. Grand View Research projects the global clinical decision support market to reach roughly $15 billion by 2033. What is not in doubt is the underlying problem. As long as safety alerts stay easy to ignore, the case for systems that clinicians actually trust looks likely to keep growing, and Seegnal now has its first American test underway to show whether its version travels. 

Recent News Highlights from Seegnal (TSXV: SEGN.V)

Seegnal to Deploy its Medication Safety Platform Across Nazareth Hospital EMMS, Expanding its Israeli Hospital Footprint

Seegnal Successfully Initiates First U.S. Pilot Program

Seegnal Accepted into Innovative Accelerator Program from AARP, the Largest U.S. Organization Serving Americans 50 and Older

Seegnal Inc. Announces Non-Brokered Private Placement

Read this Next >>

UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening (NASDAQ: GH)

Natera Announces IVDR Certification for Signatera Across Multiple Cancers (NASDAQ: NTRA)

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S. (NASDAQ: VCYT)

Jet.AI Announces Letter of Intent for New Merger and related Spin-Off of Data Center Business (NASDAQ: JTAI)

* IMPORTANT NOTICE AND DISCLAIMER: This article is sponsored content released on behalf of Seegnal Inc. ("Seegnal") and has been prepared, authored, and disseminated by Wall Street Wire. It is paid promotional content authored by the Wall Street Wire editorial team - not independent research, analysis, or journalism. As sponsored content, it carries inherent bias and potential conflicts of interest. Seegnal's role was limited to review for factual accuracy of statements about the company. This article is not an official communication of Seegnal. The article is for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation of an offer to buy any securities. Wall Street Wire is compensated for this content on a cash-based subscription arrangement; engagement details are available at https://wallstwire.ai/disclosures. The information in this article is based on publicly available sources, including Seegnal's prior press releases and filings, and has not been independently verified. Statements may constitute forward-looking information within the meaning of applicable securities laws; such statements involve risks and uncertainties, and actual results may differ materially. References to private companies, transactions, financial measures, or comparable data are drawn from publicly reported sources cited herein and are provided for thematic context only - they do not imply commercial relationships, endorsements, or comparable financial profiles with respect to Seegnal. Readers are encouraged to review Seegnal's public filings on SEDAR+ (www.sedarplus.ca) for full details, including risk factors and any reconciliations of non-GAAP financial measures referenced. Investing in securities involves risk, particularly in venture-stage and microcap issuers; readers should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. For full disclosure information, please visit wallstwire.ai/disclosures.

Contact